Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded ...

The stock's fall snapped a four-day winning streak.

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Beam Therapeutics Inc.’s BEAM share price has surged by 7.36%, which has investors questioning if this is right time to sell.

Sangamo Therapeutics, Inc.’s SGMO share price has surged by 5.70%, which has investors questioning if this is right time to sell.

Medication company Viatris (NASDAQ:VTRS) in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. The company’s full-year revenue guidance of $13.75 billion at the midpoint came in 0.5% ...

Pfizer’s positive comments about the impact of a potential tariff being manageable led the stock to increase despite a softer quarterly performance. Nonetheless, a single quarter’s results are ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... This data indicated resiliency in the labor market despite stock market uncertainty in April due to tariff concerns.

But I actually see this as a risk factor since according to my earlier analysis, Pfizer ... company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is ...

Still, Pfizer stock has fallen 10% year to date and hasn’t provided the defensive hedge that many of its Zacks Large Cap Pharmaceutical peers have been able to provide, such as AbbVie ABBV ...

saw its stock rise by 3.75% in pre-market trading, reflecting investor optimism about its earnings performance and strategic initiatives. Want deeper insights? InvestingPro analysis reveals 10+ ...